Cargando…

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth

BACKGROUND: Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T cells against solid tumors remains dissatisfactory, partially due to the heterogeneity of solid tumors and T cell exhaustion in tumor mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Le, Zhao, Ruocong, Chen, Dongmei, Wei, Xinru, Wu, Qiting, Long, Youguo, Jiang, Zhiwu, Li, Yangqiu, Wu, Haipeng, Zhang, Xuchao, Wu, Yilong, Cui, Shuzhong, Wei, Wei, Yao, Huihui, Liu, Zixia, Cao, Su, Yao, Yao, Zhang, Zhenfeng, Li, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268496/ https://www.ncbi.nlm.nih.gov/pubmed/32514352 http://dx.doi.org/10.1186/s40364-020-00198-0

Ejemplares similares

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells
por: Zhao, Ruocong, et al.
Publicado: (2018)

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
por: Lv, Jiang, et al.
Publicado: (2019)

Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
por: Qin, Le, et al.
Publicado: (2017)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
por: Zheng, Diwei, et al.
Publicado: (2022)

PSCA is a target of chimeric antigen receptor T cells in gastric cancer
por: Wu, Di, et al.
Publicado: (2020)

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis
por: Qin, Le, et al.
Publicado: (2022)

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer
por: Zhao, Ruocong, et al.
Publicado: (2021)

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D
por: Li, Shanglin, et al.
Publicado: (2022)

Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels
por: Lv, Jiang, et al.
Publicado: (2022)

Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells
por: Xiao, Yiren, et al.
Publicado: (2015)

CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression
por: Lin, Shouheng, et al.
Publicado: (2017)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)

Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia
por: Jiang, Zhiwu, et al.
Publicado: (2017)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain
por: Zhang, Ang, et al.
Publicado: (2023)

Human induced-T-to-natural killer cells have potent anti-tumour activities
por: Jiang, Zhiwu, et al.
Publicado: (2022)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
por: Yang, Ching-Yao, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
por: Lin, Zili, et al.
Publicado: (2021)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Shen, Chunyi, et al.
Publicado: (2021)

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023
por: Sun, Ming-Yao, et al.
Publicado: (2023)

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
por: Guo, Xingliang, et al.
Publicado: (2018)

Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized
por: Jiang, Zhiwu, et al.
Publicado: (2016)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments
por: Ye, Wei, et al.
Publicado: (2015)

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
por: Lin, Zili, et al.
Publicado: (2021)

Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes
por: Li, Wei, et al.
Publicado: (2015)

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
por: Jiang, Zhiwu, et al.
Publicado: (2017)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Toxic epidermal necrosis caused by programmed cell death protein 1 inhibitors in a patient receiving chimeric antigen receptor-T cell therapy
por: Wang, Chengji, et al.
Publicado: (2023)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rg(−/−) Mice Results in Severe Immunodeficiency
por: Wei, Xinru, et al.
Publicado: (2017)

Multi-epitope chimeric antigen used as a serological marker to estimate Plasmodium falciparum transmission intensity in the border area of China-Myanmar
por: Yao, Mei-Xue, et al.
Publicado: (2016)

Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
por: Wang, Haiyong, et al.
Publicado: (2021)

Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells
por: Chen, Sisi, et al.
Publicado: (2022)

Development of molecular and pharmacological switches for chimeric antigen receptor T cells
por: Wu, Bill X., et al.
Publicado: (2019)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
por: Zou, Yixin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5v2gekal7elpljtal1oqainhd1